To investigate whether loss of SMARCB1 promotes BLCA disease progression, we used an orthotopic mouse NOD/SCID/IL2rγnull (NSG) model wherein luciferase labeled T24 human bladder cancer cells (control, KO, or rescue) were directly injected into the bladder wall (orthotopic site) using two independent KO (SMARCB1 loss) clones (C16 and C45) and respective SMARCB1 rescue lines. This evidence concerns the gene SMARCB1 and urinary bladder cancer.